Rimactazid-300/Rimactazid-450 Dosage/Direction for Use

Rimactazid-300: Adults: Continuous Therapy: Body weight ≥50 kg: 2 tabs Rimactazid-300 once daily (600 rifampicin + 300 mg INH).
Intermittent Therapy: For all body weights: 2 tabs Rimactazid-300 twice or 3 times weekly (600 mg rifampicin + 300 mg INH) 2 or 3 times a week. Rimactazid has to be supplemented with 150 mg INH for every 10 kg body weight >20 kg (ie, body weight 60 kg: 150 x 4 = 600 mg additional INH needed).
Rimactazid-450: As a general rule, 1 tab once a day, taken with meals. Rimactazid-450 is designed for use in patients with a body weight of ≤50 kg.
Duration of Treatment and Combined Medication: Total Duration: 9 months. For 2 months: Rimactazid-450 (according to weight) + ethambutol 1.2 g or streptomycin 1 g daily. For 7 months: Rimactazid-450 (according to weight).
Total Duration: 6 months. For 2 months: Rimactazid-450 (according to weight) + pyrazinamide 1.5-2.5 g + ethambutol 1.2 g or streptomycin 1 g daily. For 4 months: Rimactazid-450 (according to weight) daily.
CombiPack: A triple combination (blister strip) specifically designed for the daily therapy (use in 1 single intake 7 times a week) during the first 2 months of short-course chemotherapy of tuberculosis. After completion of the first 2 months therapy, treatment should be continued daily for 4-7 months with Rimactazid-450. The content of 1 blister strip provides a dosage of rifampicin 450 mg, INH 400 mg and pyrazinamide 1500 mg, which corresponds to the dosage used in common practice for the daily treatment of a patient of ≥50 kg body weight.
CombiPack: The chemotherapeutic agents usually employed today as combined therapy for tuberculosis are rifampicin (RMP), isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB), streptomycin (STM).
The dosages recommended by the Centers for Disease Control and Prevention are as follows: See Table 2.

Click on icon to see table/diagram/image

For some drugs mentioned in the table, the dosages recommended by the CDC may differ from those recommended by WHO.
For the treatment of sputum-positive pulmonary tuberculosis, preference is nowadays given to the following regimens:
Continuous Therapy (7 times a week): Total duration 9 months: Initial phase for 2 months: RMP + INH + PZA + EMB or STM. Continuation phase for 7 months: RMP + INH.
A total duration of 9 months is recommended for tuberculosis with HIV infection, and for tuberculous meningitis, disseminated tuberculosis or spinal involvement with neurological complications.
Total duration 6 months: Initial phase for 2 months: RMP + INH + PZA + EMP or STM. Continuation phase for 4 months: RMP + INH.
Partially Intermittent Therapy: Total duration 6 months: Initial phase for 2 months: RMP + INH + PZA + EMB or STM daily. Continuation phase for 4 months: RMP + INH twice or 3 times a week.
Fully Intermittent Therapy: Total duration 6 months: RMP + INH + PZA + EMB or STM 3 times a week.
DOTS strategy (directly observed treatment, short-course ie, administration of the antituberculous agents under supervision) should be considered for all patients, irrespective of the treatment regimen they are receiving.
Dosage recommendations for sputum-negative pulmonary tuberculosis and extrapulmonary tuberculosis, and dosage recommendations for elderly and/or undernourished patients and those with severe liver damage can be found in the relevant literature.
To ensure optimum absorption, Rimactazid should preferably be taken on an empty stomach ie, at least ½ hr before a meal.
Children: In Rimactazid, the rifampicin and INH are present in a ratio which makes it hardly possible for both components to be administered in a dosage appropriate for children. Rimactazid is therefore not suitable for pediatric use.